U.S. markets closed

Cytosorbents Corporation (CTSO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
8.34+0.06 (+0.72%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Momentum

Momentum

Previous Close8.28
Open8.31
Bid7.96 x 900
Ask8.41 x 1000
Day's Range8.21 - 8.37
52 Week Range7.13 - 11.74
Volume50,133
Avg. Volume231,880
Market Cap361.283M
Beta (5Y Monthly)0.28
PE Ratio (TTM)N/A
EPS (TTM)-0.21
Earnings DateAug 02, 2021 - Aug 06, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.86
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • CytoSorbents Appoints Terri Anne Powers, IRC as Vice President of Investor Relations and Corporate Communications
    PR Newswire

    CytoSorbents Appoints Terri Anne Powers, IRC as Vice President of Investor Relations and Corporate Communications

    CytoSorbents Corporation (NASDAQ: CTSO), a critical care therapy leader commercializing its CytoSorb® blood purification technology to treat deadly conditions in critically ill and cardiac surgery patients around the world, announces the appointment of Terri Anne Powers, MBA, IRC, as Vice President of Investor Relations and Corporate Communications effective today.

  • CytoSorbents to Present at the Jefferies Virtual Healthcare Conference
    PR Newswire

    CytoSorbents to Present at the Jefferies Virtual Healthcare Conference

    CytoSorbents Corporation (NASDAQ: CTSO), a critical care leader commercializing its CytoSorb® blood purification technology to treat deadly conditions in critically ill and cardiac surgery patients around the world, announces that the Company will present an overview of the Company's progress and outlook at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021. Company management will also meet with investors in 1x1 meetings throughout the day. To schedule a meeting with management, please contact your Jefferies representative.

  • CytoSorb® Registered and Commercially Available in Singapore
    PR Newswire

    CytoSorb® Registered and Commercially Available in Singapore

    CytoSorbents Corporation (NASDAQ: CTSO), a critical care leader commercializing its CytoSorb® blood purification technology to treat deadly conditions in the intensive care unit (ICU) and cardiac surgery, announces that the Singapore Health Sciences Authority (HSA) has now approved registration of CytoSorb® for all equivalent European Union (E.U.) approved indications, including the reduction of cytokine storm, the reduction of bilirubin in liver disease, the reduction of myoglobin in trauma, and the removal of ticagrelor and rivaroxaban during urgent or emergent cardiothoracic surgery.